EFFICACY DATA
LS=least squares; OA=osteoarthritis; RA=rheumatoid arthritis; TID=3 times a day; WOMAC=Western Ontario and McMaster Universities Osteoarthritis Index, a 100 mm visual analog scale (VAS).
*This trial did not include patients treated with DUEXIS.1
†Test was measured on a Likert scale (0-4).
GASTROPROTECTION DATA
‡See Prescribing Information for alternative statistical analyses relating to such patients.2
§This analysis excludes patients who dropped out of the study prior to the first endoscopy (at 8 weeks).2
¶In REDUCE-1 (Study 303), the secondary endpoint was incidence of upper GI ulcers.2
#In REDUCE-2 (Study 301), the primary endpoint was incidence of upper GI ulcers.2
GI=gastrointestinal.
CLINICAL TRIALS PRIMARILY ENROLLED PATIENTS LESS THAN 65 YEARS OF AGE WITHOUT A PRIOR HISTORY OF GASTROINTESTINAL ULCER2
FORMULATION INFORMATION
Gastroprotection specifically engineered to match the PK profile of high-dose ibuprofen3**
Famotidine is not available as a prescription or OTC tablet in the 26.6‑mg dose, and dosing instructions do not provide for TID administration4,5
Therefore, no Rx or OTC products have been deemed therapeutically equivalent to DUEXIS2
**Phase I, randomized, open-label, crossover study in 13 healthy adults designed to compare effects on gastric pH and the safety of 80 mg of famotidine when administered in 2 vs 3 divided doses each day. Additionally, PK/PD modeling was performed to compare the effect of the dosing schedules on steady-state intragastric pH.3
NSAID=nonsteroidal anti-inflammatory drug; OTC=over the counter; PD=pharmacodynamic; PK=pharmacokinetic.
ADHERENCE CONSIDERATIONS
adherence to a gastroprotective therapy is required for risk reduction7††
††In this study, adherence to gastroprotective agents was calculated as the proportion of NSAID treatment days covered by a gastroprotective agent prescription.
These studies did not include patients being treated with DUEXIS.
‡‡Patients were classified as non-adherent to gastroprotective agents if these agents were available for less than 75% of the NSAID treatment days.
DUEXIS SUPPORT
Get more information by having your DUEXIS representative come to your practice.
REQUEST A REPRESENTATIVEOur support team is available to address
your questions and provide information
via phone (833) 438-3947.
FOR YOUR OA KNEE PAIN PATIENTS
Targeted pain relief + reduced systemic exposure of a topical
FIND OUT MOREFOR YOUR PATIENTS WITH CERTAIN INFLAMMATORY CONDITIONS
The only delayed-release prednisone for the treatment of RA and other inflammatory conditions
SEE HOW IT WORKSDUEXIS® (ibuprofen and famotidine), a combination of the NSAID ibuprofen and the histamine H2-receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of gastrointestinal ulcer. Controlled trials do not extend beyond 6 months.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.
PENNSAID® (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%) is a nonsteroidal anti-inflammatory drug indicated for the treatment of the pain of osteoarthritis of the knee(s).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.
RAYOS is a corticosteroid indicated:
Please see full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.
DUEXIS® (ibuprofen and famotidine), a combination of the NSAID ibuprofen and the histamine H2-receptor antagonist famotidine, is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers, which in the clinical trials was defined as a gastric and/or duodenal ulcer, in patients who are taking ibuprofen for those indications. The clinical trials primarily enrolled patients less than 65 years of age without a prior history of gastrointestinal ulcer. Controlled trials do not extend beyond 6 months.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.
PENNSAID® (diclofenac sodium topical solution) 2% w/w (PENNSAID 2%) is a nonsteroidal anti-inflammatory drug indicated for the treatment of the pain of osteoarthritis of the knee(s).
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.
RAYOS is a corticosteroid indicated:
Please see full Prescribing Information.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch, or call 1-800-FDA-1088.